CLDX vs IBRX
CLDX: A clinical-stage biopharmaceutical company developing mast cell-targeted monoclonal and bispecific antibodies for chronic urticaria, inflammatory skin diseases, and systemic inflammatory conditions. IBRX: ImmunityBio develops engineered natural killer cell and cancer vaccine therapies, led by its approved ANKTIVA treatment for bladder and lung cancers, to harness the immune system against cancer and infectious diseases.
Side-by-side fundamentals
| Metric | CLDX | IBRX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $34.77 | $7.51 | |
| Market cap as of 2026-07-23 | $2.7B | $8.0B | |
| PEG as of 2026-07-23 | -0.14 | -0.21 | IBRX lower |
| Net margin as of 2026-07-23 | -25011.8% | -606.1% | IBRX higher |
| Gross margin as of 2026-07-23 | +17.6% | +99.3% | IBRX higher |
| Operating margin as of 2026-07-23 | -27187.6% | -185.4% | IBRX higher |
| ROE as of 2026-07-23 | -50.7% | -193.3% | CLDX higher |
| ROA as of 2026-07-23 | -46.6% | -165.2% | CLDX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-23 | -88.5% | +351.5% | IBRX higher |
| Revenue CAGR (3y) SEC XBRL | -13.1% | +678.6% | IBRX higher |
| Beta as of 2026-07-23 | 0.82 | 0.15 | |
| 1-year return as of 2026-07-22 close | +55.5% | +177.1% | IBRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.